Imprimis Pharmaceuticals CEO Mark Baum's 2019 pay jumps 30% to $1.4M
Imprimis Pharmaceuticals reports 2019 executive compensation
By ExecPay News
Published: April 24, 2020
Imprimis Pharmaceuticals reported fiscal year 2019 executive compensation information on April 24, 2020.
In 2019, three executives at Imprimis Pharmaceuticals received on average a compensation package of $1.1M, a 55% increase compared to previous year.
Average pay of disclosed executives at Imprimis Pharmaceuticals
Mark L. Baum, Chief Executive Officer, received $1.4M in total, which increased by 30% compared to 2018. 40% of Baum's compensation, or $556K, was in option awards. Baum also received $298K in non-equity incentive plan, $489K in salary, $18K in stock awards, as well as $16K in other compensation.
Andrew R. Boll, Chief Financial Officer, received a compensation package of $1M, which increased by 90% compared to previous year. 33% of the compensation package, or $348K, was in salary.
John P. Saharek, President, ImprimisRx, earned $964K in 2019, a 66% increase compared to previous year.
Related executives
You may also like
Source: SEC filing on April 24, 2020.